[1] Mould DP, McGonagle AE, Wiseman DH, et al. Reversible inhibitors of LSD1 as therapeutic agents in acute myeloid leukemia: clinical significance and progress to date[J]. Med Res Rev, 2015, 35(3): 586-618.
[2] Short NJ, Rytting ME, Cortes JE.Acute myeloid leukaemia[J]. Lancet, 2018, 392(1014): 593-606.
[3] Richardson DR, Crossnohere NL, Seo J, et al.Age at Diagnosis and Patient Preferences for Treatment Outcomes in AML: A Discrete Choice Experiment to Explore Meaningful Benefits[J]. Cancer Epidemiol Biomarkers Prev, 2020, 29(5): 942-948.
[4] Schlenk RF, Müller-Tidow C, Benner A, et al.Relapsed/refractory acute myeloid leukemia: any progress?[J]. Curr Opin Oncol, 2017, 29(6): 467-473.
[5] Kantarjian H.Acute myeloid leukemia--major progress over four decades and glimpses into the future[J]. Am J Hematol, 2016, 91(1): 131-145.
[6] Russell EG, Guo J, O'Sullivan EC, et al. 7-formyl-10-methylisoellipticine, a novel ellipticine derivative, induces mitochondrial reactive oxygen species (ROS) and shows anti-leukaemic activity in mice[J]. Invest New Drugs, 2016, 34(1): 15-23.
[7] Lichtenegger FS, Krupka C, Köhnke T, et al.Immunotherapy for Acute Myeloid Leukemia[J]. Semin Hematol, 2015, 52(3): 207-214.
[8] Jakobsen NA, Vyas P.From genomics to targeted treatment in haematological malignancies: a focus on acute myeloid leukaemia[J]. Clin Med (Lond), 2018, 18(Suppl 2): s47-s53.
[9] Mueller BU, Seipel K, Bacher U, et al.Autologous Transplantation for Older Adults with AML[J]. Cancers (Basel), 2018, 10(9): 340.
[10] 李元明. 青蒿琥酯对人急性白血病原代细胞线粒体膜电位的影响[D].广州:广州中医药大学,2010.
[11] Bose P, Vachhani P, Cortes JE.Treatment of Relapsed/Refractory Acute Myeloid Leukemia[J]. Curr Treat Options Oncol, 2017, 18(3): 17.
[12] Wiernik PH.Inching toward cure of acute myeloid leukemia: a summary of the progress made in the last 50 years[J]. Med Oncol, 2014, 31(8): 136.
[13] Mayer LD, Tardi P, Louie AC.CPX-351: a nanoscale liposomal co-formulation of daunorubicin and cytarabine with unique biodistribution and tumor cell uptake properties[J]. Int J Nanomedicine, 2019, 14: 3819-3830.
[14] Asghari H, Lancet J.Liposomal encapsulated cytarabine and daunorubicin (CPX-351) for older patients with acute myeloid leukemia[J]. Leuk Lymphoma, 2020, 61(6): 1305-1312.
[15] Chung W, Kelly AD, Kropf P, et al.Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemia[J]. Clin Epigenetics, 2019, 11(1): 106.
[16] Heo SK, Noh EK, Jeong YK, et al.Radotinib inhibits mitosis entry in acute myeloid leukemia cells via suppression of Aurora kinase A expression[J]. Tumour Biol, 2019, 41(5): 1010428319848612.
[17] Naqvi K, Konopleva M, Ravandi F.Targeted therapies in Acute Myeloid Leukemia: a focus on FLT-3 inhibitors and ABT199[J]. Expert Rev Hematol, 2017, 10(10): 863-874.
[18] Yilmaz M, Daver N.From DNA Sequencing to Clinical Trials: Finding New Targeted Drugs for Acute Myeloid Leukemia[J]. Drugs, 2019, 79(11): 1177-1186.
[19] Short NJ, Kantarjian H, Ravandi F, et al.Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia[J]. Ther Adv Hematol, 2019, 10: 2040620719827310.
[20] Tollkuci E.Isavuconazole therapy in an FLT3 mutated acute myeloid leukemia patient receiving midostaurin: A case report[J]. J Oncol Pharm Pract, 2019, 25(4): 987-989.
[21] Becker JS, Fathi AT.Targeting isocitrate dehydrogenase mutations (IDH) in AML: wielding the double-edged sword of differentiation[J]. Curr Cancer Drug Targets, 2020, 20(7): 490-500.
[22] DiNardo CD, Stein EM, de Botton S, et al. Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML[J]. N Engl J Med, 2018, 378(25): 2386-2398.
[23] Nguyen LXT, Troadec E, Kalvala A, et al.The Bcl-2 inhibitor venetoclax inhibits Nrf2 antioxidant pathway activation induced by hypomethylating agents in AML[J]. J Cell Physiol, 2019, 234: 14040-14049.
[24] Bohl SR, Bullinger L, Rücker FG.New Targeted Agents in Acute Myeloid Leukemia: New Hope on the Rise[J]. Int J Mol Sci, 2019, 20(8): 1983.
[25] Wei AH, Montesinos P, Vladimir I, et al.Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial[J]. Blood, 2020, 135(24): 2137-2145.
[26] Cortes JE, Dombret H, Merchant A, et al.Glasdegib plus intensive/nonintensive chemotherapy in untreated acute myeloid leukemia: BRIGHT AML 1019 Phase III trials[J]. Future Oncol, 2019, 15(31): 3531-3545.
[27] Lai C, Doucette K, Norsworthy K.Recent drug approvals for acute myeloid leukemia[J]. J Hematol Oncol, 2019, 12(1): 100.
[28] Gbolahan OB, Zeidan AM, Stahl M, et al.Immunotherapeutic Concepts to Target Acute Myeloid Leukemia: Focusing on the Role of Monoclonal Antibodies, Hypomethylating Agents and the Leukemic Microenvironment[J]. Int J Mol Sci, 2017, 18(8): 1660.
[29] Lichtenegger FS, Krupka C, Haubner S, et al.Recent developments in immunotherapy of acute myeloid leukemia[J]. J Hematol Oncol, 2017, 10(1): 142.
[30] Pollyea DA.Which novel agents for acute myeloid leukemia are likely to change practice?[J]. Best Pract Res Clin Haematol, 2018, 31(4): 391-395.
[31] Yang H, Lin S, Cui J.Identifying arsenic trioxide (ATO) functions in leukemia cells by using time series gene expression profiles[J]. Gene, 2014, 535(2): 312-317.
[32] Beauchamp EM, Kosciuczuk EM, Serrano R, et al.Direct Binding of Arsenic Trioxide to AMPK and Generation of Inhibitory Effects on Acute Myeloid Leukemia Precursors[J]. Molecular Cancer Therapeutics, 2015, 14(1): 202-212.
[33] Chen Si-Si, Zhao Yan-Ping, Wu Wen-Zhong, et al.Effect of Decitabine in Combination with Arsenic Trioxide on Prolife-ration and Apoptosis of Human Acute Myeloid Leukemia MV4-11 Cells[J]. Zhongguo Shi Yan Xue Ye Xue Za Zhi, 2016, 24(5): 1343-1347.
[34] Roboz GJ, Ritchie EK, Curcio T, et al.Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia[J]. Cancer, 2008, 113(9): 2504-2511.
[35] 张明发,沈雅琴.苦参碱类生物碱抗粒细胞和单核细胞性白血病的药理作用研究进展[J].抗感染药学,2019,16(4): 559-563.
[36] 任汝静. 三氧化二砷联合青蒿琥酯对急性早幼粒细胞白血病体内外实验研究[D].北京:中国中医科学院,2018.
[37] Komiya T, Yamada Y, Moteki H, et al.Hot water soluble sesquiterpenes [anhydroperoxy- costunolide and 3-oxoeudesma-1, 4(15), 11(13) triene-12, 6alpha-olide] isolated from laurel (Laurus nobilis L.) induce cell death and morphological change indicative of apoptotic chromatin condensation in leukemia cells[J]. Oncol Rep, 2004, 11(1): 85-88.
[38] Formisano C, Sirignano C, Rigano D, et al.Antiproliferative activity against leukemia cells of sesquiterpene lactones from the Turkish endemic plant Centaurea drabifolia subsp. detonsa[J]. Fitoterapia, 2017, 120: 98-102.
[39] Zhou J, Han N, Lv G, et al.Two New β-Dihydroagarofuran Sesquiterpenes from Celastrus orbiculatus Thunb and Their Anti-Proliferative Activity[J]. Molecules, 2017, 22(6): 948.
[40] 徐昊淼. 浙贝黄芩汤通过调控Wip1抗白血病并缓解炎症反应的机制研究[D].北京:北京中医药大学,2019. |
